• Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.

    NIH licenses COVID-19 technologies to WHO-backed program

    The agreement, which covers three experimental vaccines as well as several key patents, will be royalty free for products sold in 49 low-income countries.

    By May 13, 2022
  • Image attribution tooltip
    SciePro via Getty Images

    Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

    The deal hands $275 million upfront to Cullinan, whose medicine is being developed for a genetic driver of lung tumors that's become a top target for drugmakers.

    By Kristin Jensen • May 12, 2022
  • Trendline

    The BioPharma Dive Outlook on 2022

    After surging into 2021, biotech crashed at the end of last year amid negative clinical trial readouts, ebbing M&A and broader investor pullback. But the year ahead figures to be busy on several fronts and a slate of important studies could deliver good news. 

    By BioPharma Dive staff
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs

    The deal, which hands Pfizer full rights to the biotech's fast-selling Nurtec ODT, could provide a much needed spark for the sector after months of stock market declines. 

    By , Updated May 10, 2022
  • Image attribution tooltip
    Permission granted by Biogen

    Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

    Though executives claimed that inking deals and derisking research programs are priorities, analysts questioned whether any meaningful strategic changes will occur in the near term. 

    By May 4, 2022
  • Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    A cancer biotech attracts another deep-pocketed partner in Gilead

    Following rivals like Bristol Myers Squibb and Merck, Gilead has linked up with Dragonfly Therapeutics to develop new immunotherapies based on "natural killer cell engagers."

    By May 2, 2022
  • Image attribution tooltip

    A promising cancer drug leads Regeneron to reconsider its aversion to M&A

    Regeneron has agreed to purchase Checkmate Pharmaceuticals for $250 million, the first acquisition of a publicly traded company in the biotech's nearly 35-year history.

    By April 19, 2022
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B

    Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.  

    By April 13, 2022
  • Image attribution tooltip
    Warren Little via Getty Images

    GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

    The British pharma is buying into the potential of a medicine meant to treat the anemia often associated with myelofibrosis, a complication that isn't adequately addressed by current therapies.

    By , April 13, 2022
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Pfizer, Moderna name new finance chiefs amid surging revenue

    Pfizer is bringing in former Lowe's and CVS Health executive David Denton, while Moderna hired Jorge Gomez, previously CFO at Cardinal Health. Both take the reins as their new companies face strategic questions.

    By April 11, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer buys a private biotech and its RSV drug research

    The pharma company will add experimental RSV treatments to its pipeline through the deal, which is worth up to $525 million.

    By Kristin Jensen • April 7, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Regeneron, in search of an eye gene therapy, turns to a young biotech

    Facing mounting competition to its top-selling drug Eylea, Regeneron is teaming up with ViGeneron to develop a genetic medicine for an inherited retinal disease.

    By April 6, 2022
  • Image attribution tooltip
    Courtesy of Sanofi

    Sanofi pays IGM $150M, continuing search for better antibody drugs

    The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines.

    By March 29, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    Pfizer claims study success for drug key to Arena buyout

    Etrasimod, the basis of the $7 billion acquisition and a potential rival to Bristol Myers Squibb's Zeposia, has cleared the first of two trials in ulcerative colitis. 

    By Kristin Jensen • March 23, 2022
  • Image attribution tooltip
    AscentXmedia via Getty Images

    GSK partners with LifeMine as startups advance plans to make drugs from fungi

    The deal, announced alongside a $175 million round, makes biotech entrepreneur Greg Verdine's startup the most well-funded among an emerging group of companies searching for drugs in fungal DNA.

    By March 23, 2022
  • Image attribution tooltip
    Permission granted by Biogen

    Biogen and its partner rework terms of Aduhelm deal amid slow sales

    Instead of sharing global profits and losses, Eisai will receive royalties tied to net sales of the Alzheimer's drug. Biogen, meanwhile, said the amended deal should make it easier to "address market developments."

    By March 15, 2022
  • Image attribution tooltip
    Courtesy of Sanofi

    Sanofi lures Blackstone backing in unusual deal for multiple myeloma drug

    Rather than fund development of a more convenient version of its blood cancer drug Sarclisa on its own, Sanofi has instead turned to Blackstone, which has fast become one of the sector's more active investors.

    By Kristin Jensen • March 15, 2022
  • Image attribution tooltip

    AbbVie keeps up dealmaking pace in neuroscience

    On the heels of its Syndesi acquisition, the company has announced an agreement with Gedeon Richter focused on researching and developing new dopamine-regulating drugs for neuropsychiatric diseases.

    By March 11, 2022
  • Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.

    After slower-than-expected review, Pfizer and Arena close buyout deal

    Pfizer officially closed its $7 billion acquisition of Arena Pharmaceuticals on Friday without needing to divest any assets.

    By Updated March 11, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Novartis turns to Voyager for nervous system gene therapies

    The deal, which carries a $54 million upfront payment, could give Novartis access to as many as five of Voyager's capsids, which would be used to develop gene therapies for the central nervous system.

    By March 8, 2022
  • Bluebird's CFO resigns as cash woes raise doubts about its future

    The gene therapy developer's top financial executive, Gina Consylman, is stepping down amid concerns the company needs to raise additional cash to survive for more than a year.  

    By March 7, 2022
  • Image attribution tooltip
    Courtesy of Biocon

    Viatris sells off biosimilars business in $3.3B deal

    The sale to Biocon represents the first major step Viatris has taken to reshape itself, following a strategic review that took place throughout 2021.

    By Feb. 28, 2022
  • Image attribution tooltip
    Getty Images

    Biohaven stocks up on experimental drugs with new acquisition, licensing deal

    Separate agreements with Channel Biosciences and Bristol Myers Squibb give Biohaven access to experimental treatments for spinal muscular atrophy and for epilepsy.

    By Feb. 25, 2022
  • Image attribution tooltip

    James Thew/

    Sponsored by TrialCard

    Copay accumulators, maximizers and the CMS best price rule: What you need to know now

    Copay accumulators, maximizers and best price concerns dominated the copay assistance landscape in 2021. Here is an update on the most prominent developments in this area over the last six months.

    By Jason Zemcik, Vice President, Patient Affordability, TrialCard • Feb. 22, 2022
  • Image attribution tooltip
    Getty Images

    Pressed by Wall Street, pharma executives signal openness to M&A

    Despite tumbling biotech valuations, however, several said they still prefer smaller-sized "bolt-on" deals to larger, potentially more disruptive, transactions.

    By Feb. 7, 2022
  • Image attribution tooltip
    Courtesy of Intellia Therapeutics

    Intellia, expanding in gene editing, buys startup Rewrite for $45M

    Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's. 

    By Feb. 3, 2022